MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa2025797

Медицинская библиотека · The New England journal of medicine · 2020

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

Teerlink John R, Diaz Rafael, Felker G Michael, McMurray John J V, Metra Marco, Solomon Scott D, Adams Kirkwood F, Anand Inder, Arias-Mendoza Alexandra, Biering-Sørensen Tor, Böhm Michael, Bonderman Diana, Cleland John G F, Corbalan Ramon, Crespo-Leiro Maria G, Dahlström Ulf, Echeverria Luis E, Fang James C, Filippatos Gerasimos, Fonseca Cândida, Goncalvesova Eva, Goudev Assen R, Howlett Jonathan G, Lanfear David E, Li Jing, Lund Mayanna, Macdonald Peter, Mareev Viacheslav, Momomura Shin-Ichi, O'Meara Eileen, Parkhomenko Alexander, Ponikowski Piotr, Ramires Felix J A, Serpytis Pranas, Sliwa Karen, Spinar Jindrich, Suter Thomas M, Tomcsanyi Janos, Vandekerckhove Hans, Vinereanu Dragos, Voors Adriaan A, Yilmaz Mehmet B, Zannad Faiez, Sharpsten Lucie, Legg Jason C, Varin Claire, Honarpour Narimon, Abbasi Siddique A, Malik Fady I, Kurtz Christopher E, GALACTIC-HF Investigators

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown.

METHODS

We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes.

RESULTS

During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups.

CONCLUSIONS

Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.).

Для цитирования: Teerlink John R, Diaz Rafael, Felker G Michael, McMurray John J V, Metra Marco, Solomon Scott D, Adams Kirkwood F, Anand Inder, Arias-Mendoza Alexandra, Biering-Sørensen Tor, Böhm Michael, Bonderman Diana, Cleland John G F, Corbalan Ramon, Crespo-Leiro Maria G, Dahlström Ulf, Echeverria Luis E, Fang James C, Filippatos Gerasimos, Fonseca Cândida, Goncalvesova Eva, Goudev Assen R, Howlett Jonathan G, Lanfear David E, Li Jing, Lund Mayanna, Macdonald Peter, Mareev Viacheslav, Momomura Shin-Ichi, O'Meara Eileen, Parkhomenko Alexander, Ponikowski Piotr, Ramires Felix J A, Serpytis Pranas, Sliwa Karen, Spinar Jindrich, Suter Thomas M, Tomcsanyi Janos, Vandekerckhove Hans, Vinereanu Dragos, Voors Adriaan A, Yilmaz Mehmet B, Zannad Faiez, Sharpsten Lucie, Legg Jason C, Varin Claire, Honarpour Narimon, Abbasi Siddique A, Malik Fady I, Kurtz Christopher E, GALACTIC-HF Investigators. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.. The New England journal of medicine. 2020. DOI: 10.1056/nejmoa2025797.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.